| Literature DB >> 18187921 |
Munetaka Hirose1, Mayumi Takatori, Yoshihiro Kuroda, Mineo Abe, Eri Murata, Tetsuro Isada, Koyo Ueda, Kenji Shigemi, Masayuki Shibazaki, Fumihiro Shimizu, Masashi Hirata, Keita Fukazawa, Masahiro Sakaguchi, Kyoko Kageyama, Yoshifumi Tanaka.
Abstract
As TrkA, a high-affinity receptor of nerve growth factor (NGF), is a potential target for relieving uncontrolled inflammatory pain, an effective inhibitor of TrkA has been required for pain management. To identify a specific inhibitor of TrkA activity, we designed cell-penetrating peptides combined with amino-acid sequences in the activation loop of TrkA to antagonize tyrosine kinase activity. To select a peptide inhibiting TrkA activity, we examined the effect of cell-penetrating peptides on tyrosine kinase activity of recombinant TrkA in vitro and studied their effects on NGF-stimulated neurite outgrowth and protein phosphorylation in PC12 cells. Thereafter we investigated the effect of the selected peptide on NGF-stimulated TrkA activity and the expression of transient receptor potential channel 1 in PC12 cells. The selected peptide inhibited TrkA activity, but did not inhibit tyrosine kinase activities of other receptor-type tyrosine kinases in vitro. It also suppressed NGF-stimulated responses in PC12 cells. The selected synthetic cell-penetrating peptide antagonizing TrkA function would be a candidate for inflammatory pain therapy.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18187921 DOI: 10.1254/jphs.fpz070263
Source DB: PubMed Journal: J Pharmacol Sci ISSN: 1347-8613 Impact factor: 3.337